The New England journal of medicine
The most recent articles from:
N. Engl. J. Med.
-
Historical Article
A Legacy of Cruelty to Sexual and Gender Minority Groups.
-
Randomized Controlled Trial Multicenter Study
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.
Dual agonism of glucagon receptor and glucagon-like peptide-1 (GLP-1) receptor may be more effective than GLP-1 receptor agonism alone for treating metabolic dysfunction-associated steatohepatitis (MASH). The efficacy and safety of survodutide (a dual agonist of glucagon receptor and GLP-1 receptor) in persons with MASH and liver fibrosis are unclear. ⋯ Survodutide was superior to placebo with respect to improvement in MASH without worsening of fibrosis, warranting further investigation in phase 3 trials. (Funded by Boehringer Ingelheim; 1404-0043 ClinicalTrials.gov number, NCT04771273; EudraCT number, 2020-002723-11.).